Pulmonary sarcomatoid carcinoma: University of Cincinnati experience

Nagla Abdel Karim, James Schuster, Ihab Eldessouki, Ola Gaber, Tariq Namad, Jiang Wang, Changchun Xie, John C. Morris

Research output: Contribution to journalArticlepeer-review

37 Scopus citations


Objectives: To review the outcomes of treatment in patients with pulmonary sarcomatoid carcinoma (PSC) treated at the University of Cincinnati Medical Center (UCMC). Results: There was no significant difference in survival of patients treated with chemotherapy alone (median, 256 days) compared to patients not undergoing treatment (median, 205.5 days). Patients who underwent surgery and adjuvant chemotherapy showed a trend in improvement of survival (median, 457.6 days). Patients requiring only surgery had the longest OS of 713.5 days. Conclusions: Systemic chemotherapy alone did not improve survival in patients with PSC. Surgery provides the greatest overall survival benefit and adjuvant chemotherapy may also improve survival. Methods: From 2000 to 2014, twenty-five patients with pathologically confirmed PSC were treated at UCMC. The outcomes were retrospectively analyzed by treatment with overall survival (OS) as the endpoint.

Original languageEnglish (US)
Pages (from-to)4102-4108
Number of pages7
Issue number3
StatePublished - 2018


  • Chemotherapy
  • Lung cancer
  • Non-small cell lung cancer
  • Sarcomatoid

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Pulmonary sarcomatoid carcinoma: University of Cincinnati experience'. Together they form a unique fingerprint.

Cite this